Obstructive sleep apnea, GLP-1 receptor agonist pharmacotherapy, and the oral microbiome: competing biological influences and implications for oral health monitoring.

PURPOSE: Obstructive sleep apnea (OSA) is associated with reproducible oral microbiome dysbiosis mediated by five simultaneous biological pathways: chronic intermittent hypoxia-driven immune dysregulation, obligate mouth breathing causing salivary desiccation, elevated salivary glucose promoting cariogenic biofilm proliferation, gastroesophageal reflux acid challenge, and hypothalamic-pituitary-adrenal axis activation suppressing mucosal immunity. The December 2024 FDA approval of tirzepatide for moderate-to-severe OSA and the emergence of retatrutide and orforglipron have placed GLP-1 receptor agonists (GLP-1RAs) at the center of OSA pharmacotherapy. This review examines the oral microbiome consequences of GLP-1RA therapy in OSA patients, characterizes the competing biological influences these agents introduce, and identifies the monitoring and research implications of the resulting uncertainty. METHODS: A narrative review of published literature examining OSA-related oral microbiome dysbiosis, GLP-1RA pharmacological mechanisms relevant to oral biology, salivary gland pharmacovigilance data, and gut microbiome restoration evidence. Sources included PubMed, Web of Science, and Scopus databases searched through June 2026. RESULTS: GLP-1RA therapy engages five restoration pathways that mechanistically counter each OSA-driven dysbiosis mechanism: direct AHI reduction, attenuating hypoxia-driven immune dysregulation; pharyngeal airway improvement, reducing obligate mouth breathing; glycemic normalization, reducing salivary fermentable substrate; gastric emptying delay and weight loss, attenuating GERD acid challenge; and sleep architecture restoration, reducing cortisol-mediated mucosal immune suppression. Pharmacovigilance data, however, indicate that semaglutide may impair salivary gland responsiveness through β-arrestin-mediated receptor desensitization-a competing oral risk that partially or fully counteracts the restoration benefits. Tirzepatide's biased agonism profile (preferential activation of cAMP signaling over β-arrestin internalization) may confer differential salivary gland safety, and orforglipron's daily oral dosing introduces direct oropharyngeal drug exposure with uncharacterized microbiological consequences. The net oral microbiome outcome in any treated patient is the product of these competing influences and has not been characterized prospectively. CONCLUSIONS: GLP-1RA pharmacotherapy in OSA creates a biologically complex oral microbiome environment whose clinical trajectory cannot be predicted from current evidence. Prospective studies are warranted, oral health monitoring beginning at treatment initiation is scientifically justified, and seven priority research questions are identified at the convergence of sleep medicine, endocrinology, and oral biology.